Brain test may predict Alzheimer's drug response

NCT ID NCT03703856

Completed Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether simple brain function measures can predict which Alzheimer's patients will respond to the drug memantine. 53 participants with mild-to-moderate Alzheimer's took memantine or placebo, then all received memantine for 24 weeks. The goal was to see if early brain responses could guide personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Memantine
What this could lead to: If successful, this could help doctors predict which Alzheimer's patients will benefit most from memantine, leading to more personalized treatment.
What could go wrong: This is a small, completed Phase 4 study with only 53 participants, so results may not apply to all Alzheimer's patients. The benefit of memantine is modest and not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Clinical Teaching Facility (CTF-B102) at UCSD Medical Center

San Diego, California, 92103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.